JESSICA ADAMS: Open Payments
NPI 1841484060 · NEWPORT NEWS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,738 in 85 payments from 17 companies in 2025. Trend: 2023 $4,180 · 2024 $2,285 · 2025 $1,738
Food & beverage: $1,738
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $349 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $286 |
| ABBVIE INC. | 19 | $257 |
| E.R. Squibb & Sons, L.L.C. | 10 | $238 |
| Supernus Pharmaceuticals, Inc. | 6 | $160 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Alkermes, Inc. | 3 | $61 |
| Corium, LLC | 3 | $53 |
| Janssen Pharmaceuticals, Inc | 3 | $46 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, COBENFY, Qelbree, FANAPT, ARISTADA, REXULTI.
Industry payments across VA — which companies pay providers there.
